CYDY
OQB CytoDyn Inc.$0.1989 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.1989, $0.0061 below the day’s high of $0.2050
- YTD change
- -28.97%
- vs 20-day SMA
- -3.54%
- vs 200-day SMA
- -22.04%
Price ranges
Price & Performance
-0.13 (-40.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.0% away from all-time highs of $10.0100
- CYDY is down 29% since the beginning of the year
- CYDY is down 25% over the past 12 months
- CYDY is up 1% over the past 1 month
- 3% of all CYDY investors are betting against CYDY
CYDY reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -28.5%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0010
- Last 5 days
- -0.56%
- vs 8-day SMA
- -0.58%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development and potential commercialization of its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its current clinical development activities focus on solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer, and the development of a long-acting version of leronlimab. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
